A summary of this Week’s headlining NEJM article : Health Care Renewal: A "Tune-Up" from Nesiritide?.
Not a very good endorsement of this latest wonder drug:
Topol concluded, "in my view, nesiritide has not yet met the minimal criteria for safety and efficacy." So, "we need a tune-up of our procedures to eliminate indiscriminate use of drugs, such as nesiritide, when there is not proper evidence of their safety."
I wonder what he has in mind for that procedure? I thought that was the FDA’s role.
But, that makes it easy. Just Say No, at least for now. (And, this again verifies the truism for new drug use: Never be the first to try it, never be the last to adopt it). I wrote about this earlier, and, to my knowledge, none of my colleagues are using it now either.
via DB’s MedRants